Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2020

13.04.2019 | Original Research

Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer

verfasst von: Divya Yerramilli, Lorraine Drapek, Ryan D. Nipp, Nora Horick, Samantha M. C. Moran, Bridget Noé, Sara M. D’Arpino, Devarati Mitra, Theodore S. Hong, David P. Ryan, Don S. Dizon, Jennifer Wo

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose/Objective(s)

Definitive chemoradiation (CRT) results in high cure rates of anal cancer, with advanced radiation (RT) techniques improving toxicity. However, there is limited data regarding these patients’ sexual function (SF), quality of life (QOL), and mood. We hypothesized that anal cancer treatment would result in detrimental effects on SF, QOL, and mood.

Materials/Methods

We prospectively surveyed patients with anal cancer treated with definitive CRT. We assessed SF for women with the Female Sexual Function Index (FSFI) and for men with the International Index of Erectile Function (IIEF). For all patients, we assessed QOL using EORTC QLQ-C30 and CR29 and mood using the Hospital Anxiety and Depression Scale (HADS). We reported descriptive statistics for SF, QOL, and mood and used univariate analysis to evaluate predictors of SF for women.

Results

Of 50 eligible patients, 84% completed the surveys. Median time from RT until survey was 36 months (1–97 months). Women (n = 34) reported poor SF overall (mean FSFI score = 15, scale 2–36, standard deviation (SD) 10.4). Most women reported poor SF related to satisfaction, desire, orgasm, arousal, pain, and lubrication. Men (n = 8) also had poor overall satisfaction (mean IIEF score = 6.1, scale 2–10, SD 3.6). Men reported poor erectile function and lower satisfaction with intercourse. Mean QLQ-C30 QOL score was 86.5 (SD 16.3). Results from EORTC QLQ-CR-20 demonstrated patients experienced poor sexual interest. Per HADS, 2.5% reported depression and 18% anxiety.

Conclusion

Patients with anal cancer experience sexual dysfunction after RT, with QOL and mood symptoms similar to patients with other cancers. Our data support the need for ongoing efforts to understand and address issues with SF, QOL, and mood following RT for these patients.
Literatur
1.
Zurück zum Zitat Nigro ND, Vaitkevicius V, Buroker T, Bradley G, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24:73–5.PubMedCrossRef Nigro ND, Vaitkevicius V, Buroker T, Bradley G, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24:73–5.PubMedCrossRef
2.
Zurück zum Zitat Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMedCrossRef Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMedCrossRef
3.
Zurück zum Zitat Bartelink H, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.PubMedCrossRef Bartelink H, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.PubMedCrossRef
4.
Zurück zum Zitat James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol. 2009;27:LBA4009.CrossRef James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol. 2009;27:LBA4009.CrossRef
5.
Zurück zum Zitat Allal A, Sprangers M, Laurencet F, Reymond M, Kurtz J. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer. 1999;80:1588–94.PubMedPubMedCentralCrossRef Allal A, Sprangers M, Laurencet F, Reymond M, Kurtz J. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer. 1999;80:1588–94.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010;116:822–9.PubMedCrossRef Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010;116:822–9.PubMedCrossRef
7.
Zurück zum Zitat Sodergren SC, et al. Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Support Care Cancer. 2015;23:3613–23.PubMedCrossRef Sodergren SC, et al. Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Support Care Cancer. 2015;23:3613–23.PubMedCrossRef
8.
Zurück zum Zitat Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52:736–44.PubMedCrossRef Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52:736–44.PubMedCrossRef
9.
Zurück zum Zitat Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:1012–7.PubMedCrossRef Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:1012–7.PubMedCrossRef
10.
11.
Zurück zum Zitat Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23:7428–36.PubMedCrossRef Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23:7428–36.PubMedCrossRef
12.
Zurück zum Zitat Coady D, Kennedy V. Sexual health in women affected by cancer: focus on sexual pain. Obstet Gynecol. 2016;128:775–91.PubMedCrossRef Coady D, Kennedy V. Sexual health in women affected by cancer: focus on sexual pain. Obstet Gynecol. 2016;128:775–91.PubMedCrossRef
13.
Zurück zum Zitat Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014;120:3870–83.PubMedCrossRef Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014;120:3870–83.PubMedCrossRef
14.
Zurück zum Zitat Han K, Cummings BJ, Lindsay P, Skliarenko J, Craig T, le LW, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90:587–94.PubMedCrossRef Han K, Cummings BJ, Lindsay P, Skliarenko J, Craig T, le LW, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90:587–94.PubMedCrossRef
15.
Zurück zum Zitat Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2:110–7.PubMedPubMedCentralCrossRef Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2:110–7.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37:461–6.PubMedCrossRef Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37:461–6.PubMedCrossRef
17.
Zurück zum Zitat Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, et al. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol. 2015;5:e113–8.PubMedCrossRef Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, et al. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol. 2015;5:e113–8.PubMedCrossRef
18.
Zurück zum Zitat Kachnic LA, et al. NRG oncology/RTOG 0529: long-term outcomes of dose-painted intensity modulated radiation therapy, 5-fluorouracil, and mitomycin-C in anal canal cancer. Int J Radiat Oncol Biol Phys. 2017;99:S64–5.CrossRef Kachnic LA, et al. NRG oncology/RTOG 0529: long-term outcomes of dose-painted intensity modulated radiation therapy, 5-fluorouracil, and mitomycin-C in anal canal cancer. Int J Radiat Oncol Biol Phys. 2017;99:S64–5.CrossRef
19.
Zurück zum Zitat Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.PubMedCrossRef Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.PubMedCrossRef
20.
Zurück zum Zitat Carter J, Stabile C, Seidel B, Baser RE, Gunn AR, Chi S, et al. Baseline characteristics and concerns of female cancer patients/survivors seeking treatment at a female sexual medicine program. Support Care Cancer. 2015;23:2255–65.PubMedPubMedCentralCrossRef Carter J, Stabile C, Seidel B, Baser RE, Gunn AR, Chi S, et al. Baseline characteristics and concerns of female cancer patients/survivors seeking treatment at a female sexual medicine program. Support Care Cancer. 2015;23:2255–65.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Baser RE, Li Y, Carter J. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer. 2012;118:4606–18.PubMedCrossRef Baser RE, Li Y, Carter J. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer. 2012;118:4606–18.PubMedCrossRef
22.
Zurück zum Zitat Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.PubMedCrossRef Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.PubMedCrossRef
23.
Zurück zum Zitat Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.PubMedCrossRef Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.PubMedCrossRef
24.
Zurück zum Zitat Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597–601.PubMedCrossRef Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597–601.PubMedCrossRef
25.
Zurück zum Zitat Rosen RC, Cappelleri J, Smith M, Lipsky J, Pena B. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.PubMedCrossRef Rosen RC, Cappelleri J, Smith M, Lipsky J, Pena B. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.PubMedCrossRef
26.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRef
28.
Zurück zum Zitat Whistance R, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45:3017–26.CrossRefPubMed Whistance R, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45:3017–26.CrossRefPubMed
29.
Zurück zum Zitat Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002;52:69–77.CrossRefPubMed Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002;52:69–77.CrossRefPubMed
30.
Zurück zum Zitat Son CH, Law E, Oh JH, Apte AP, Yang TJ, Riedel E, et al. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. Int J Radiat Oncol Biol Phys. 2015;92:548–54.PubMedPubMedCentralCrossRef Son CH, Law E, Oh JH, Apte AP, Yang TJ, Riedel E, et al. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. Int J Radiat Oncol Biol Phys. 2015;92:548–54.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Carroll BT, Kathol RG, Noyes R, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. Gen Hosp Psychiatry. 1993;15:69–74.PubMedCrossRef Carroll BT, Kathol RG, Noyes R, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. Gen Hosp Psychiatry. 1993;15:69–74.PubMedCrossRef
32.
Zurück zum Zitat Sellick SM, Edwardson AD. Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psycho-Oncology. 2007;16:534–42.PubMedCrossRef Sellick SM, Edwardson AD. Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psycho-Oncology. 2007;16:534–42.PubMedCrossRef
33.
Zurück zum Zitat Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef
34.
Zurück zum Zitat Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.PubMedCrossRef Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.PubMedCrossRef
35.
Zurück zum Zitat Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24:3669–76.PubMedPubMedCentralCrossRef Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24:3669–76.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patientreported outcomes. Wiley; 2013. Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patientreported outcomes. Wiley; 2013.
37.
Zurück zum Zitat Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–63.PubMedCrossRef Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–63.PubMedCrossRef
38.
Zurück zum Zitat Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278–300.PubMedCrossRef Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278–300.PubMedCrossRef
40.
Zurück zum Zitat Nipp Ryan D, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017;123:4720–7.PubMedCrossRef Nipp Ryan D, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017;123:4720–7.PubMedCrossRef
42.
Zurück zum Zitat Wo JY, Drapek LC, Niemierko A, Silvia BL, Russo AL, Gray PJ, et al. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation. Int J Rad Oncol Biol Phys. 2017;96(2):E528–9.CrossRef Wo JY, Drapek LC, Niemierko A, Silvia BL, Russo AL, Gray PJ, et al. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation. Int J Rad Oncol Biol Phys. 2017;96(2):E528–9.CrossRef
43.
Zurück zum Zitat Fisher RJ. Social desirability bias and the validity of indirect questioning. J Consum Res. 1993;20:303–15.CrossRef Fisher RJ. Social desirability bias and the validity of indirect questioning. J Consum Res. 1993;20:303–15.CrossRef
Metadaten
Titel
Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer
verfasst von
Divya Yerramilli
Lorraine Drapek
Ryan D. Nipp
Nora Horick
Samantha M. C. Moran
Bridget Noé
Sara M. D’Arpino
Devarati Mitra
Theodore S. Hong
David P. Ryan
Don S. Dizon
Jennifer Wo
Publikationsdatum
13.04.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00233-w

Weitere Artikel der Ausgabe 1/2020

Journal of Gastrointestinal Cancer 1/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.